Strasbourg-based RDS, a French MedTech firm, immediately introduced a €14 million Collection A funding spherical for its distant monitoring and wearable patch, with the intention to speed up its improvement in France, Germany and the broader European market.
The SPI (Sociétés de Projets Industriels) fund, managed on behalf of the French state by Bpifrance, led the spherical, with Essential Path Ventures additionally taking a brand new stake. MACSF, Capital Grand Est and different historic traders additionally contributed.
With this financing, RDS could have raised a complete of €28 million since its founding. The Collection A €14 million comes on prime of the €14 million in capital and non-dilutive financing offered by the French authorities, notably by way of the France 2030 funding plan.
“This funding offers us the means to ramp up our gross sales progress in Europe, consolidate the medical and well being financial worth of MultiSense, and prepare for market launch in North America,” mentioned Elie Lobel, CEO of RDS.
He added: “These funds imply we will roll out our answer extra broadly to hospitals, develop its optimistic impression for sufferers and care groups, and supply dependable, steady, clinically validated distant monitoring to as many services as potential. The funds raised are a testomony to our traders’ enduring confidence on this venture and the staff.”
Based in 2020, RDS specialises in distant affected person monitoring, creating, manufacturing and advertising MultiSense, a distant medical monitoring answer. RDS depends on a global staff and collaborates with main analysis tasks corresponding to DARE and 5G-OR. Incubated at SEMIA/Quest for Well being and accelerated by PariSanté Campus, it goals to redefine telemonitoring requirements by way of patented expertise and an eco-conscious strategy.
The MultiSense answer combines a wearable patch with a cloud-based platform and related help companies. It constantly displays six key parameters, together with coronary heart price, respiratory price and oxygen saturation.
From the outset, sustainability has been a core focus: the gadget will be cleaned, refurbished and reused to minimise its carbon footprint. MultiSense is designed to help the implementation of short-stay hospitalisation protocols, aiming to assist cut back the common size of hospital stays, to make sure safer hospital discharge and to enhance sufferers’ high quality of life.
“France 2030 is proud to have supported this venture since 2020 and to work immediately with SPI on the speedy industrialisation and efficient deployment of the answer for the good thing about sufferers. RDS’ story clearly reveals how France 2030 is able to transitioning a venture from the lab stage to changing into a global champion,” mentioned Bruno Bonnell, Secretary Basic for Funding, in command of France 2030.
RDS’ Collection A matches right into a broader surge of funding flowing into European HealthTech in 2025. In response to our previous coverage, HealthTech was essentially the most funded tech sector in Q1 2025 (bringing in €4.42 billion in non-public funding). Two related developments start to rise when contemplating different funding rounds on this sector:
-
Wearable/monitoring/gadget scale: ViCentra’s €72.4 million Series D round underscores how differentiated medical units (in that case, insulin patch pumps) are attracting important capital once they mix usability, regulatory readiness, and medical integration.
-
Imaging and diagnostic instruments: Rounds corresponding to PIUR IMAGING’s progress capital present that AI-augmented imaging and diagnostic units are additionally drawing sustained investor curiosity, particularly when bridging into new geographies.
Relative to those, RDS’ elevate is average in dimension however significant, particularly for a Collection A within the MedTech {hardware} + medical trials house. Its deal with scaling industrialisation, reimbursement, and European rollout is carefully aligned with what traders have rewarded elsewhere.
“We’re delighted to be supporting RDS on this vital part of its improvement,” mentioned Magali Joëssel, director of the SPI fund at Bpifrance. “This funding offers the corporate the means to change into a number one participant in post-operative distant monitoring by way of MultiSense, and a pioneer within the medication of the long run. By scaling the manufacturing of its answer, RDS totally embodies the precept of the SPI fund: funding the industrialisation of revolutionary applied sciences that may carry progress and jobs to France.”
Their clinically validated expertise has already been rolled out in 15 hospitals throughout France, Belgium and Germany. Within the final 12 months, the gadget was added to the authorised provides listing for RESAH and UniHA, main public buying our bodies for hospitals in France.
The corporate expects to create a number of hundred new jobs by 2035, bolstering its gross sales staff to fulfill the demand for the MultiSense answer. The funds will even finance the industrialisation of the answer that’s manufactured in France, with the purpose of progressively ramping up manufacturing and refurbishing capacities.
Concurrently, RDS will launch complementary medical trials to help its functions for reimbursement in France and throughout Europe. The corporate can also be making ready to provoke the FDA registration course of, with a view to a US market launch in 2028.
“We imagine that the important thing to remodeling the healthcare system is helpful innovation and industrial ambition,” mentioned Nicolas Foessel of Essential Path Ventures. “With our funding in RDS, we’re backing a staff that mixes technological excellence with medical impression and a long-term imaginative and prescient for medication, with emphasis on a extra preventive, smoother and human strategy. MultiSense exemplifies this positioning, enabling steady monitoring and assembly sufferers’ specific wants away from the hospital setting.”
In parallel with this funding spherical, Laurent Monnin, senior funding director at Bpifrance, joins the corporate’s strategic board, as does Nicolas Foessel, representing Essential Path Ventures.
“The funding offered by SPI and Essential Path Ventures is an actual asset for RDS, which can have the ability to ramp-up actions after a launch part to which MACSF and Capital Grand Est have contributed,” mentioned Jean-François Rax, associate at Capital Grand Est.
